We assume that the Ang-2 levels secreted by endothelial cells from tumor-associated blood vessels are sufficient to efficiently modulate the angiogenic balance in the tumor environment and influence the effect of bevacizumab, but that Ang-2 may not be released into the circulation to the same extent and therefore may not reflect the conditions in the tumor compartment. Here, ANGPT2 is linked to neoplasm.